Biopharma Program To Collaborate on OI
The Drug Discovery and Development website reported that the biopharmaceutical company AstraZeneca and Taiwan’s National Research Program for Biopharmaceuticals have announced a collaborative program to support academic research proposals using open innovation as a catalyst for drug discovery. The program will connect expert physicians and scientists with a wide range of high-quality, small molecule compounds and biologics developed by AstraZeneca.
Click here to read the full article.